Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

ConditionsNon Alcholic Fatty Liver Disease Hepatic Steatosis Hepatic Fibrosis NAFLD (Nonalcoholic Fatty Liver Disease)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorAssiut University

About this trial

evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age >18 years

both sex

Disqualifiers

alcohol drinker

any cause of liver affection (hepatitis, autoimmune…etc)

patients with kidney function affection

Trial population

All patients aged over 18 years, not alcohol drinker,has any cause of liver affection,or with kidney function affection

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

determine the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic fibrosis and steatosis in patients with NAFLD using fibroscan and biomarkers

Time frame

Baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: